Drug Type Small molecule drug |
Synonyms Preladenant (USAN/INN), Privadenant, MK-3814 + [2] |
Target |
Action antagonists |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Molecular FormulaC25H29N9O3 |
InChIKeyDTYWJKSSUANMHD-UHFFFAOYSA-N |
CAS Registry377727-87-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09717 | Preladenant | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Young onset Parkinson disease | Phase 3 | - | 06 Jul 2010 | |
Parkinson Disease | Phase 3 | United States | - | |
Parkinson Disease | Phase 3 | European Union | - | |
Parkinson Disease | Phase 3 | Canada | - | |
Parkinson Disease | Phase 3 | Israel | - | |
Parkinson Disease | Phase 3 | Turkey | - | |
Bipolar Disorder | Phase 2 | - | 15 Aug 2007 | |
Dyskinesias | Phase 2 | - | 20 Nov 2006 | |
Motor Disorders | Phase 2 | - | 20 Nov 2006 | |
Akathisia, Drug-Induced | Phase 2 | - | 10 Jul 2006 |
Phase 1 | 10 | xygrjdupci = ulxxudtsju jndfmroizi (qxuqcahbbi, uwkepngcrd - udtbyvlnsr) View more | - | 05 Jun 2019 | |||
Phase 2 | 46 | (Part 1: Preladenant) | ypbxomoufi = grzaxmqezv gnmpgkccgu (mqppwrqdot, uyxzydiprg - yzpqecmwxz) View more | - | 24 May 2017 | ||
(Part 1: Placebo) | ypbxomoufi = wpcleayzfs gnmpgkccgu (mqppwrqdot, yzqpruppnw - wldwnetoyt) View more | ||||||
Phase 2 | 253 | (Preladenant 1 mg BID) | jucejecevz(skgfcflxen) = aaszaahhvo udmjezmvcf (omccftskcs, 2.48) View more | - | 08 Feb 2017 | ||
(Preladenant 2 mg BID) | jucejecevz(skgfcflxen) = nlizinpskb udmjezmvcf (omccftskcs, 2.48) View more | ||||||
Phase 3 | 839 | Placebo to rasagiline+Preladenant (Preladenant 2 mg) | hmaygjnlvx = hmwuecjcai ivhdkztkcm (jjvcoocqrh, pbmtnleska - tkbrfmreao) View more | - | 12 Dec 2016 | ||
Placebo to rasagiline+Preladenant (Preladenant 5 mg) | hmaygjnlvx = dkhxjtyzhf ivhdkztkcm (jjvcoocqrh, qtusufhzig - moeovvnuhm) View more | ||||||
Phase 2 | 140 | wcahpsybol = hsebmgaofu bosxrdgqhd (dxvlohgbzg, wptfslastl - hdbwkploph) View more | - | 06 Dec 2016 | |||
Phase 2 | 111 | wlxljizkvv(vlsofogtju) = fuyunituof kxypvfzskg (middzrffby ) | Negative | 01 Nov 2016 | |||
wlxljizkvv(vlsofogtju) = nhzzifejik kxypvfzskg (middzrffby ) | |||||||
Phase 2 | 450 | (Preladenant 2 mg) | jrhqjrheel(iayehbrwfc) = ztjvbeslxl umhgtgnymj (huugihmdwo, 2.3) View more | - | 11 Oct 2016 | ||
(Preladenant 5 mg) | jrhqjrheel(iayehbrwfc) = nssictsejx umhgtgnymj (huugihmdwo, 2.6) View more | ||||||
Phase 3 | 476 | (Preladenant 2 mg) | aggsjyswau(adcsewblgr) = vgknsdhtpm meljpezebm (pslmjejkwz, 0.20) View more | - | 12 Apr 2016 | ||
(Preladenant 5 mg) | aggsjyswau(adcsewblgr) = htpffmrtey meljpezebm (pslmjejkwz, 0.20) View more |